CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

Published: 17-Apr-2024

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase

CordenPharma, a global CDMO specialising in the manufacturing of Drug Substance (APIs) complex modalities and injectable Drug Products and GENEPEP, a French CRO specialising in the design, chemical synthesis and optimisation of peptides and proteins, have celebrated one year of their fruitful collaboration.

The partnership — signed in 2023 — supports biotech companies with the development, discovery and manufacturing of peptides for early clinical phase, leveraging CordenPharma’s cGMP manufacturing capacities, regulatory know-how and market access, as well as GENEPEP’s discovery and drug development expertise. 

Under the terms of the agreement, GENEPEP provides services for research and discovery activities, as well as support for initial Investigational New Drug (IND) application packages, including selection of lead and alternative compounds for discovery purpose, research-grade samples including testing reports, process familiarisation and development. 

In addition, they supply gram peptide manufacturing samples representative of tox quality, ensuring a smooth and seamless transition to the CordenPharma Frankfurt site for early clinical GMP manufacturing, along with access to their global sales and marketing organisation.

Dr Stéphane Varray, CordenPharma’s Global Peptide Platform Director, commented: “With our new early clinical GMP peptide manufacturing investment in Frankfurt and the strategic partnership with GENEPEP, we are proud to strengthen our peptide offering for biotech and pharma customers in early discovery to First-In-Human clinical stage. In the past 12 months, we have demonstrated together how this collaboration has simplified and expedited the milestones of lead development and validation in a clinical setting.”




You may also like